Salbutamol, Pharmacogenetics and Breathing Mechanics

Bronchoconstriction Clinical Trial

Official title: The Pharmacogenetic Effects of Inhaled Salbutamol on Breathing Mechanics and Cycling Performance

Status Completed

Clinical Trial Summary

Athletes using asthma medications called β2-agonists win a disproportionately high number of medals at Olympic Games. Due to a large variety in the genes that affect how individuals respond to β2-agonists, the investigators will look at variations in the genetic response to these medications by dividing athletes into high-responders and low-responders. The investigators will then compare athletic performance after the inhalation of β2-agonists to placebo. Furthermore, the investigators will analyze the effect of β2-agonists on breathing mechanics. Due to differences in their anatomy females may decrease the energy needed for breathing during high-intensity exercise to a greater extent compared to male athletes after the inhalation of β2-agonists.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Bronchoconstriction
• Cycling Performance
• Inhaled Salbutamol
• Respiratory Aspiration

• NCT number: NCT01903785
• Study type: Interventional
• Source: University of British Columbia
• Status: Completed
• Phase: Phase 4
• Start date: May 2013
• Completion date: August 2016